Publicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (11)

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2018

  1. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer

    Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329

  2. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial

    Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444

2017

  1. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

    European Journal of Cancer, Vol. 81, pp. 191-202

2015

  1. Current controversies in the management of metastatic colorectal cancer

    Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 659-677

  2. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

2011

  1. Fructose transporter GLUT5 expression in clear renal cell carcinoma

    Oncology Reports, Vol. 25, Núm. 2, pp. 315-323

  2. New insights into molecular mechanisms of sunitinib-associated side effects

    Molecular Cancer Therapeutics, Vol. 10, Núm. 12, pp. 2215-2223

2010

  1. Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters

    Molecular Medicine Reports, Vol. 3, Núm. 4, pp. 575-580